n°116

May 2011

Issue Contents
Editorial

Free  The time factor

p.116
For quality treatment decisions

Marketing Authorisations

Prucalopride (New Drug)

p.117-120
In chronic constipation: poorly documented risks

Serotonin agonist or "hidden" neuroleptic?

p.119

INN common-stem: -prost-

p.120

Quadrivalent papillomavirus vaccine in women aged over 26 (New Indication)

p.121
Cervical screening must remain a priority

Autologous chondrocytes (New Drug)

p.122-124
Autologous chondrocyte implantation: more data needed

Adverse Effects

Free  Nimesulide: patients still exposed to a risk of severe hepatitis

p.125-126
Use another NSAID

Azathioprine and mercaptopurine: lymphoma

p.126
A follow-up cohort of 19 486 patients

Poppers: methaemoglobinaemia; respiratory, cardiac and visual disorders

p.127
A review of French cases

Terpene derivatives: still on the market for use in children

p.127
No proven efficacy but a clear risk of seizures

Rivastigmine patches: fatal overdoses

p.127
Another reason not to use

Reviews

Treatment-resistant depression: no panacea, many uncertainties

p.128-133
Adverse effects are a major factor in treatment choice

Prescrire's advice: choosing a treatment for drug-resistant depression

p.131

Outlook

Free  The finances of Association Mieux Prescrire

p.134-135
2010 Prescrire annual report

Free  Prescrire's proposals to France's national conference on medicines policy: patients' interests and public health should come first

p.136-138
57 proposals on how to get medicines policy back on track

Free  Patient education: keep the best, avoid the rest

p.138
Beware of commercially biased education

Free  Prescrire is wholly self-financed

p.140

Masthead

Free  Masthead

p.114

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe